Canine spontaneous glioma: A translational model system for convection-enhanced delivery

Neuro-Oncology

Volumn 12, Issue 9, 2010, Pages 928-940

  Dickinson, Peter J ^a   LeCouteur, Richard A ^a   Higgins, Robert J ^a   Bringas, John R ^b   Larson, Richard F ^a   Yamashita, Yoji ^b   Krauze, Michal T ^b   Forsayeth, John ^b   Noble, Charles O ^b,c   Drummond, Daryl C ^c   Kirpotin, Dmitri B ^c   Park, John W ^b   Berger, Mitchel S ^b   Bankiewicz, Krystof S ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c MERRIMACK PHARMACEUTICALS   (United States)

Author keywords

Brain tumors; Canine; Convectionenhanced delivery; CPT 11; Magnetic resonance imaging

Indexed keywords

GADOTERIDOL; IRINOTECAN; LIPOSOME;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTOMA; BRAIN VENTRICLE; CANCER SURVIVAL; CONTROLLED STUDY; CONVECTION ENHANCED DELIVERY SYSTEM; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG INFUSION; EXPERIMENTAL DOG; GLIOBLASTOMA; GLIOMA; HISTOPATHOLOGY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIOMA; PHENOTYPE; SUBARACHNOID SPACE; THERMODYNAMICS; TUMOR NECROSIS; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BRAIN NEOPLASMS; CAMPTOTHECIN; CONVECTION; DISEASE MODELS, ANIMAL; DOGS; DRUG DELIVERY SYSTEMS; GLIOMA; LIPOSOMES; MAGNETIC RESONANCE IMAGING; NANOPARTICLES;

EID: 78650087670     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/noq046     Document Type: Article

References (60)

1. Fomchenko EI, Holland EC. Mouse models of brain tumors and their applications in preclinical trials. Clin Cancer Res. 2006;12:5288-5297.
2. Branle F, Lefranc F,Camby I, et al. Evaluation of the efficiencyof chemotherapy in in vivo orthotopic models of human glioma cells with and without 1p19q deletions and in C6 rat orthotopic allografts serving for the evaluation of surgery combined with chemotherapy. Cancer. 2002;95:641-655.
3. Vail DM, MacEwen EG. Spontaneously occurring tumors of companion animals as models for human cancer. Cancer Invest. 2000;18:781-792.
4. Koestner A, Bilzer T, Fatzer R, Schulman FY, Summers BA, Van Winkle TJ. Histological Classification of Tumors of the Nervous System of Domestic Animals. 2nd ed, vol. 5. Washington, D.C: The Armed Forces Institute of Pathology; 1999.
5. Paoloni M, Khanna C. Translation of new cancer treatments from pet dogs to humans. Nat Rev Cancer. 2008;8:147-156.
6. Kimmelman J, Nalbantoglu J. Faithful companions: a proposal for neurooncology trials in pet dogs. Cancer Res. 2007;67:4541-4544.
7. Surawicz TS, McCarthy BJ, Kupelian V, Jukich PJ, Bruner JM, Davis FG. Descriptive epidemiology of primary brain and CNS tumors: results from the Central Brain Tumor Registry of the United States, 1990-1994. Neuro Oncol. 1999;1:14-25.
8. McKinney PA. Brain tumours: incidence, survival, and aetiology. J Neurol Neurosurg Psychiatry. 2004;75(suppl 2):ii12-ii17.
9. Klotz M. Incidence of brain tumors in patients hospitalized for chronic mental disorders. Psychiatr Q. 1957;31:669-680.
10. McGrath JT. Intracranial pathology of the dog. Acta Neuropathol (Berl). 1962;1(suppl I):3-4.
11. Schneider R. General considerations. In: Moulton, JE ed. Tumors in Domestic Animals. 2nd ed. Berkley: University of California Press; 1978:1-15.
12. PriesterWA, McKay FW. The occurrence of tumors in domestic animals. In: Ziegler, JL ed. National Cancer Institute Monograph. Bethseda, MD: U.S. Department of Health and Human Services; 1980:1-210.
13. Candolfi M, Curtin JF, Nichols WS, et al. Intracranial glioblastoma models in preclinical neuro-oncology: neuropathological characterization and tumor progression. J Neurooncol. 2007;85:133-148.
14. Summers BA, Cummings JF, de Lahunta A. Tumors of the Central Nervous System. Veterinary Neuropathology St Louis: Mosby; 1995:351-401.
15. Vandevelde M, Fankhauser R, Luginbü hl H. Immunocytochemical studies in canine neuroectodermal brain tumors. Acta Neuropathol (Berl). 1985;66:111-116.
16. Sturges BK, Dickinson PJ, Bollen AW, et al. Magnetic resonance imaging and histological classification of intracranial meningiomas in 112 dogs. J Vet Intern Med. 2008;22:586-595.
17. Stoica G, Kim HT, Hall DG, Coates JR. Morphology, immunohistochemistry, and genetic alterations in dog astrocytomas. Vet Pathol. 2004;41:10-19.
18. Westworth DR, Dickinson PJ, Vernau W, et al. Choroid plexus tumors in 56 dogs (1985-2007). J Vet Intern Med. 2008;22:1157-1165.
19. Snyder JM, Shofer FS, Van Winkle TJ, Massicotte C. Canine intracranial primary neoplasia: 173 cases (1986-2003). J Vet Intern Med. 2006;20:669-675.
20. Thomas WB, Wheeler SJ, Robert K, Kornegay JN. Magnetic resonance imaging features of primary brain tumors in dogs. Vet Radiol Ultrasound. 1996;37:20-27.
21. Kraft SL, Gavin PR, DeHaan C, Moore M, Wendling LR, Leathers CW. Retrospective review of 50 canine intracranial tumors evaluated by magnetic resonance imaging. J Vet Intern Med. 1997;11:218-225.
22. Lipsitz D, Higgins RJ, Kortz GD, Dickinson PJ, Bollen AW, LeCouteur RA. Glioblastoma multiforme: clinical findings, magnetic resonance imaging and pathology in 5 dogs. Vet Pathol. 2003;40:659-669.
23. Dickinson PJ, Roberts BN, Higgins RJ, et al. Expression of receptor tyrosine kinases VEGFR-1 (FLT-1), VEGFR-2 (KDR), EGFR-1, PDGFRa and c-Met in canine primary brain tumors. Vet Comp Oncol. 2006;4:132-140.
24. Dickinson PJ, Sturges BK, Higgins RJ, et al. Vascular endothelial growth factor mRNA expression and peritumoral edema in canine primary central nervous system tumors. Vet Pathol. 2008;45:131-139.
25. Debinski W, Gibo DM, Wykosky J, Stanton C, Rossmeisl J, Robertson J. Canine gliomas over-express IL-13Ralpha2, EphA2 and Fra-1 in common with human high-grade astrocytomas. Neuro Oncol. 2007;9:535.
26. Stoica G, Lungu G, Stoica H, Waghela S, Levine J, Smith R, 3rd. Identification of cancer stem cells in dog glioblastoma. Vet Pathol. 2009;
27. Thomson SA, Kennerly E, Olby N, et al. Microarray analysis of differentially expressed genes of primary tumors in the canine central nervous system. Vet Pathol. 2005;42:550-558.
28. Platt SR, Scase TJ, Adams V, et al. Vascular endothelial growth factor expression in canine intracranial meningiomas and association with patient survival. J Vet Intern Med. 2006;20:663-668.
29. Long S, Argyle DJ, Nixon C, et al. Telomerase reverse transcriptase (TERT) expression and proliferation in canine brain tumours. Neuropathol Appl Neurobiol. 2006;32:662-673.
30. Thomas R, Duke SE, Wang HJ, et al. 'Putting our heads together': insights into genomic conservation between human and canine intracranial tumors. J Neurooncol. 2009;94:333-349.
31. Higgins RJ, Dickinson PJ, Lecouteur RA, et al. Spontaneous canine gliomas: overexpression of EGFR, PDGFRalpha and IGFBP2 demonstrated by tissue microarray immunophenotyping [published online ahead of print December 5, 2009]. J Neurooncol. 2009.
32. Dickinson PJ, Surace EI, Cambell M, et al. Expression of the tumor suppressor genes NF2, 4.1B, and TSLC1 in canine meningiomas. Vet Pathol. 2009;46:884-892.
33. Debinski W, Tatter SB. Convection-enhanced delivery for the treatment of brain tumors. Expert Rev Neurother. 2009;9:1519-1527.
34. Potmesil M. Camptothecins: from bench research to hospital wards. Cancer Res. 1994;54:1431-1439.
35. Hare CB, Elion GB, Houghton PJ, et al. Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)- carbonyloxy- camptothecin against pediatric and adult central nervous system tumor xenografts. Cancer Chemother Pharmacol. 1997;39:187-191.
36. Feun L, Savaraj N. Topoisomerase I inhibitors for the treatment of brain tumors. Expert Rev Anticancer Ther. 2008;8:707-716.
37. Saito R, Krauze MT, Bringas JR, et al. Gadolinium-loaded liposomes allow for real-time magnetic resonance imaging of convection-enhanced delivery in the primate brain. Exp Neurol. 2005;196:381-389. (Pubitemid 41607827)
38. Krauze MT, McKnight TR, Yamashita Y, et al. Real-time visualization and characterization of liposomal delivery into the monkey brain by magnetic resonance imaging. Brain Res Brain Res Protoc. 2005;16:20-26.
39. Noble CO, Krauze MT, Drummond DC, et al. Novel nanoliposomal CPT-11 infused by convection-enhanced delivery in intracranial tumors: pharmacology and efficacy. Cancer Res. 2006;66: 2801-2806.
40. Dickinson PJ, LeCouteur RA, Higgins RJ, et al. Canine model of convection-enhanced delivery of liposomes containing CPT-11 monitored with real-time magnetic resonance imaging: laboratory investigation. J Neurosurg. 2008;108:989-998.
41. Bankiewicz KS, Eberling JL, Kohutnicka M, et al. Convection-enhanced delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach. Exp Neurol. 2000;164:2-14.
42. Higgins RJ, LeCouteur RA, Vernau KM, Sturges BK, Obradovich JE, Bollen AW. Granular cell tumor of the canine central nervous system: two cases. Vet Pathol. 2001;38:620-627.
43. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK. WHO classification of tumors of the central nervous system. 4th ed. Geneva: WHO Press; 2007.
44. Varenika V, Dickinson P, Bringas J, et al. Detection of infusate leakage in the brain using real-time imaging of convection-enhanced delivery. J Neurosurg. 2008;109:874-880.
45. Krauze MT, Noble CO, Kawaguchi T, et al. Convection-enhanced delivery of nanoliposomal CPT-11 (irinotecan) and PEGylated liposomal doxorubicin (Doxil) in rodent intracranial brain tumor xenografts. Neuro Oncol. 2007;9:393-403.
46. Saito R, Krauze MT, Noble CO, et al. Convection-enhanced delivery of Ls-TPT enables an effective, continuous, low-dose chemotherapy against malignant glioma xenograft model. Neuro-oncology. 2006;8: 205-214.
47. Yamashita Y, Krauze MT, Kawaguchi T, et al. Convection-enhanced delivery of a topoisomerase I inhibitor (nanoliposomal topotecan) and a topoisomerase II inhibitor (pegylated liposomal doxorubicin) in intracranial brain tumor xenografts. Neuro-oncology. 2007; 9:20-28.
48. Saito R, Bringas JR, McKnight TR, et al. Distribution of liposomes into brain and rat brain tumor models by convection-enhanced delivery monitored with magnetic resonance imaging. Cancer Res. 2004;64: 2572-2579.
49. Kaneda N, Nagata H, Furuta T, Yokokura T. Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse. Cancer Res. 1990;50:1715-1720.
50. Atsumi R, Okazaki O, Hakusui H. Metabolism of irinotecan to SN-38 in a tissue-isolated tumor model. Biol Pharm Bull. 1995;18:1024-1026.
51. Guichard S, Terret C, Hennebelle I, et al. CPT-11 converting carboxylesterase and topoisomerase activities in tumour and normal colon and liver tissues. Br J Cancer. 1999;80:364-370.
52. Kawato Y, Furuta T, Aonuma M, Yasuoka M, Yokokura T, Matsumoto K. Antitumor activity of a camptothecin derivative, CPT-11, against human tumor xenografts in nude mice. Cancer Chemother Pharmacol. 1991;28:192-198.
53. Ohtsuka K, Inoue S, Kameyama M, et al. Intracellular conversion of irinotecan to its active form, SN-38, by native carboxylesterase in human non-small cell lung cancer. Lung Cancer. 2003;41:187-198.
54. Nagai S, Yamauchi M, Andoh T, et al. Establishment and characterization of human gastric and colonic xenograft lines resistant to CPT-11 (a new derivative of camptothecin). J Surg Oncol. 1995;59:116-124.
55. Niimi S, Nakagawa K, Sugimoto Y, et al. Mechanism of cross-resistance to a camptothecin analogue (CPT-11) in a human ovarian cancer cell line selected by cisplatin. Cancer Res. 1992;52:328-333.
56. Hu ZP, Yang XX, Chen X, Chan E, Duan W, Zhou SF. Simultaneous determination of irinotecan (CPT-11) and SN-38 in tissue culture media and cancer cells by high performance liquid chromatography: application to cellular metabolism and accumulation studies. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;850:575-580.
57. Sanghani SP, Quinney SK, Fredenburg TB, et al. Carboxylesterases expressed in human colon tumor tissue and their role in CPT-11 hydrolysis. Clin Cancer Res. 2003;9:4983-4991.
58. Zhang W, Xu G, McLeod HL. Comprehensive evaluation of carboxylesterase-2 expression in normal human tissues using tissue array analysis. Appl Immunohistochem Mol Morphol. 2002;10: 374-380.
59. Yamada T, Hosokawa M, Satoh T, et al. Immunohistochemistry with an antibody to human liver carboxylesterase in human brain tissues. Brain Res. 1994;658:163-167. (Pubitemid 24291715)
60. Furihata T, Hosokawa M, Satoh T, Chiba K. Synergistic role of specificity proteins and upstream stimulatory factor 1 in transactivation of the mouse carboxylesterase 2/microsomal acylcarnitine hydrolase gene promoter. Biochem J. 2004;384:101-110.